Talha Munir

Talha Munir is a CLL specialist and clinical investigator who has contributed to landmark trials of BTK inhibitors and venetoclax combinations including the FLAIR trial comparing fixed-duration ibrutinib-venetoclax to chemotherapy in fit CLL patients. His clinical research focuses on time-limited treatment approaches offering deep remissions and treatment-free intervals. He has been involved in multiple phase III trials shaping modern CLL treatment and has contributed to UK CLL treatment guidelines. He is an emerging leader in European CLL research.